Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
We recently reported a tumor-rejection antigen, SART1259, possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs). This study investigated the expression of SART1259 antigen in osteosarcoma and other skeletal malignant tumors to explore for a potential molecule for use in specific immunotherapy. The SART1259 antigen was detected in the cytosol fraction of 13 of 21 (62%) osteosarcoma cell lines and 3 of 8 (38%) osteosarcoma tissues, and 3 of 10 (30%) malignant fibrous histiocytoma (MFH) tissues. The HLA-A24+ and SART1259+ osteosarcoma cells were recognized by the HLA-A24 restricted and SART1 specific CTLs. These results raise a possibility that the SART1259 would be an appropriate molecule for use in specific immunotherapy of approximately one-third of HLA-A24+ patients with osteosarcoma and MFH.
Ishida
H
H
Departments of Orthopaedic Surgery and Immunology, Kurume University School of Medicine, Japan.
Komiya
S
S
Inoue
Y
Y
Yutani
S
S
Inoue
A
A
Itoh
K
K
D000951:Antigens, Neoplasm / Q000032:analysis*; D001859:Bone Neoplasms / Q000737:chemistry* / Q000276:immunology; D003600:Cytosol / Q000737:chemistry; D015234:HLA-A Antigens / Q000032:analysis; D059871:HLA-A24 Antigen; D018219:Histiocytoma, Benign Fibrous / Q000737:chemistry / Q000276:immunology; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis*; D012516:Osteosarcoma / Q000737:chemistry* / Q000276:immunology; D017411:Ribonucleoproteins, Small Nuclear; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D009363:Neoplasm Proteins; D017411:Ribonucleoproteins, Small Nuclear; C431323:SART1 protein, human